Curaleaf (OTCMKTS:CURLF) Upgraded by Roth Capital to “Strong-Buy” Rating

Roth Capital upgraded shares of Curaleaf (OTCMKTS:CURLF) to a strong-buy rating in a research note released on Sunday morning,Zacks.com reports. Roth Capital also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.21) EPS.

A number of other analysts have also issued reports on CURLF. Needham & Company LLC restated a “buy” rating and issued a $6.25 price target on shares of Curaleaf in a research note on Thursday, August 8th. Cormark lowered shares of Curaleaf from a “moderate buy” rating to a “hold” rating in a research note on Thursday, November 7th.

Curaleaf Stock Up 9.8 %

Shares of OTCMKTS:CURLF opened at $2.24 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85. The company has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.74. The firm has a market cap of $1.46 billion, a PE ratio of -7.72 and a beta of 0.86. Curaleaf has a 12-month low of $1.64 and a 12-month high of $6.40.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.